Table 4.

Predicted mean (95% CI)^* tau pathology by APOE ε4 carrier status

	Year of death, 1997–2011	Year of death, 2012–2017
	Adjusted Mean NFTs	Adjusted Mean NFT density	Adjusted Mean tau burden
Model 1
APOE ε4 positive	16.0 (6.5–39.3)	16.8 (9.8–18.6)	54.3 (30.2–97.6)
APOE ε4 negative	6.8 (5.1–9.1)	8.7 (6.8–11.3)	24.6 (18.7–32.3)
Model 2
APOE ε4 positive	19.4 (7.0–53.9)	12.0 (6.9–21.0)	44.8 (24.7–81.2)
APOE ε4 negative	6.6 (5.0–8.8)	8.9 (7.0–11.4)	24.7 (18.9–32.3)

^*Results are based on negative binomial regression. Bolded results are significantly different between APOE positive and negative at 0.05. Model 1 includes APOE, Model 2 includes both APOE and amyloid pathology. For NFTs, the amyloid measure was diffuse plaque counts; amyloid density was used for NFT density; and amyloid burden was used for tau burden. All models were adjusted for age at death and sex.